543 related articles for article (PubMed ID: 18242053)
1. Pregnancy outcome in women with inflammatory bowel disease following exposure to 5-aminosalicylic acid drugs: a meta-analysis.
Rahimi R; Nikfar S; Rezaie A; Abdollahi M
Reprod Toxicol; 2008 Feb; 25(2):271-5. PubMed ID: 18242053
[TBL] [Abstract][Full Text] [Related]
2. Outcomes of infants born to mothers with inflammatory bowel disease: a population-based cohort study.
Dominitz JA; Young JC; Boyko EJ
Am J Gastroenterol; 2002 Mar; 97(3):641-8. PubMed ID: 11926208
[TBL] [Abstract][Full Text] [Related]
3. The effect on the fetus of medications used to treat pregnant inflammatory bowel-disease patients.
Moskovitz DN; Bodian C; Chapman ML; Marion JF; Rubin PH; Scherl E; Present DH
Am J Gastroenterol; 2004 Apr; 99(4):656-61. PubMed ID: 15089898
[TBL] [Abstract][Full Text] [Related]
4. The fetal safety of thiopurines for the treatment of inflammatory bowel disease in pregnancy.
Hutson JR; Matlow JN; Moretti ME; Koren G
J Obstet Gynaecol; 2013 Jan; 33(1):1-8. PubMed ID: 23259868
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic drug use in women with Crohn's disease and birth outcomes: a Danish nationwide cohort study.
Nørgård B; Pedersen L; Christensen LA; Sørensen HT
Am J Gastroenterol; 2007 Jul; 102(7):1406-13. PubMed ID: 17437503
[TBL] [Abstract][Full Text] [Related]
6. Pregnancy and inflammatory bowel disease: a prospective case-control study.
Malgarinos G; Gikas A; Delicha E; Stamataki A; Georgopoulos F; Papadimitriou A; Stanciu C; Triantafillidis JK
Rev Med Chir Soc Med Nat Iasi; 2007; 111(3):613-9. PubMed ID: 18293689
[TBL] [Abstract][Full Text] [Related]
7. Birth outcome in women exposed to 5-aminosalicylic acid during pregnancy: a Danish cohort study.
Nørgård B; Fonager K; Pedersen L; Jacobsen BA; Sørensen HT
Gut; 2003 Feb; 52(2):243-7. PubMed ID: 12524407
[TBL] [Abstract][Full Text] [Related]
8. Dipyrone use during pregnancy and adverse perinatal events.
da Silva Dal Pizzol T; Schüler-Faccini L; Mengue SS; Fischer MI
Arch Gynecol Obstet; 2009 Mar; 279(3):293-7. PubMed ID: 18568358
[TBL] [Abstract][Full Text] [Related]
9. Pregnancy before and after the diagnosis of inflammatory bowel diseases: retrospective case-control study.
Bortoli A; Saibeni S; Tatarella M; Prada A; Beretta L; Rivolta R; Politi P; Ravelli P; Imperiali G; Colombo E; Pera A; Daperno M; Carnovali M; de Franchis R; Vecchi M;
J Gastroenterol Hepatol; 2007 Apr; 22(4):542-9. PubMed ID: 17376049
[TBL] [Abstract][Full Text] [Related]
10. Ondansetron in pregnancy and risk of adverse fetal outcomes.
Pasternak B; Svanström H; Hviid A
N Engl J Med; 2013 Feb; 368(9):814-23. PubMed ID: 23445092
[TBL] [Abstract][Full Text] [Related]
11. Pregnancy and nursing.
Burakoff R; Opper F
Gastroenterol Clin North Am; 1995 Sep; 24(3):689-98. PubMed ID: 8809243
[TBL] [Abstract][Full Text] [Related]
12. Management of inflammatory bowel diseases during pregnancy.
Dignass AU; Hartmann F; Sturm A; Stein J
Dig Dis; 2009; 27(3):341-6. PubMed ID: 19786762
[TBL] [Abstract][Full Text] [Related]
13. Early pregnancy azathioprine use and pregnancy outcomes.
Cleary BJ; Källén B
Birth Defects Res A Clin Mol Teratol; 2009 Jul; 85(7):647-54. PubMed ID: 19343728
[TBL] [Abstract][Full Text] [Related]
14. Inflammatory bowel disease: management issues during pregnancy.
Ferrero S; Ragni N
Arch Gynecol Obstet; 2004 Sep; 270(2):79-85. PubMed ID: 12721680
[TBL] [Abstract][Full Text] [Related]
15. Pregnancy in inflammatory bowel disease: effect of sulfasalazine and corticosteroids on fetal outcome.
Mogadam M; Dobbins WO; Korelitz BI; Ahmed SW
Gastroenterology; 1981 Jan; 80(1):72-6. PubMed ID: 6108894
[TBL] [Abstract][Full Text] [Related]
16. The relationship of asthma medication use to perinatal outcomes.
Schatz M; Dombrowski MP; Wise R; Momirova V; Landon M; Mabie W; Newman RB; Hauth JC; Lindheimer M; Caritis SN; Leveno KJ; Meis P; Miodovnik M; Wapner RJ; Paul RH; Varner MW; O'Sullivan MJ; Thurnau GR; Conway DL; ;
J Allergy Clin Immunol; 2004 Jun; 113(6):1040-5. PubMed ID: 15208581
[TBL] [Abstract][Full Text] [Related]
17. [Pregnancy outcome in inflammatory bowel diseases].
Tennenbaum R; Marteau P; Elefant E; Rambaud JC; Modigliani R; Gendre JP; Cosnes J
Gastroenterol Clin Biol; 1999 May; 23(5):464-9. PubMed ID: 10429848
[TBL] [Abstract][Full Text] [Related]
18. Exposure to mesalamine during pregnancy increased preterm deliveries (but not birth defects) and decreased birth weight.
Sachar D
Gut; 1998 Sep; 43(3):316. PubMed ID: 9863473
[No Abstract] [Full Text] [Related]
19. Safety of high doses of mesalazine during pregnancy.
Marteau P; Seksik P; Couve S; Jian R
Am J Gastroenterol; 2005 Aug; 100(8):1897-8. PubMed ID: 16086733
[No Abstract] [Full Text] [Related]
20. Pregnancy and newborn outcome of mothers with inflammatory bowel diseases exposed to anti-TNF-α therapy during pregnancy: three-center study.
Bortlik M; Machkova N; Duricova D; Malickova K; Hrdlicka L; Lukas M; Kohout P; Shonova O; Lukas M
Scand J Gastroenterol; 2013 Aug; 48(8):951-8. PubMed ID: 23834232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
